1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011; 103(9): 714-36. [DOI:10.1093/jnci/djr077]

2. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015; 314(23): 2535-43. [DOI:10.1001/jama.2015.16669]

3. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-96. [DOI:10.1056/NEJMoa043330]

4. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699-708. [DOI:10.1056/NEJMoa1308573]

5. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 709-22. [DOI:10.1056/NEJMoa1308345]

6. Chédeville AL, Madureira PA. The role of hypoxia in glioblastoma radiotherapy resistance. Cancers. 2021; 13(3): 542. [DOI:10.3390/cancers13030542]

7. Ali MY, Oliva CR, Noman ASM, Allen BG, Goswami PC, Zakharia Y, et al. Radioresistance in glioblastoma and the development of radiosensitizers. Cancers. 2020; 12(9): 2511. [DOI:10.3390/cancers12092511]

8. Li H-F, Kim J-S, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 2009; 4: 43. [DOI:10.1186/1748-717X-4-43]

9. Kim Y, Kim KH, Lee J, Lee Y, Kim M, Lee SJ, et al. Wnt activation is implicated in glioblastoma radioresistance. Lab Invest. 2012; 92(3): 466-73. [DOI:10.1038/labinvest.2011.161]

10. Papavassiliou KA, Papavassiliou AG. Transcription factors in glioblastoma-molecular pathogenesis and clinical implications. Biochim Biophys Acta Rev Cancer. 2022; 1877(1): 188667. [DOI:10.1016/j.bbcan.2021.188667]

11. Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis. 2014; 5(11): e1543. [DOI:10.1038/cddis.2014.509]

12. Bache M, Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, et al. Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiat Oncol. 2011; 6: 111. [DOI:10.1186/1748-717X-6-111]

13. Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021; 171: 105780. [DOI:10.1016/j.phrs.2021.105780]

14. Liao K, Ma X, Chen B, Lu X, Hu Y, Lin Y, et al. Upregulated AHIF-mediated radioresistance in glioblastoma. Biochem Biophys Res Commun. 2019; 509(2): 617-23. [DOI:10.1016/j.bbrc.2018.12.136]

15. Zheng R, Yao Q, Ren C, Liu Y, Yang H, Xie G, et al. Upregulation of long noncoding RNA small nucleolar RNA host gene 18 promotes radioresistance of glioma by repressing semaphorin 5A. Int J Radiat Oncol Biol Phys. 2016; 96(4): 877-87. [DOI:10.1016/j.ijrobp.2016.07.036]

16. Brodie S, Lee HK, Jiang W, Cazacu S, Xiang C, Poisson LM, et al. The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. Oncotarget. 2017; 8(19): 31785-801. [DOI:10.18632/oncotarget.15991]

17. Memon A, Lee WK. KLF10 as a tumor suppressor gene and its TGF-β signaling. Cancers. 2018;10(6):161. [DOI:10.3390/cancers10060161]

18. Subramaniam M, Hawse JR, Rajamannan NM, Ingle JN, Spelsberg TC. Functional role of KLF10 in multiple disease processes. Biofactors. 2010; 36(1): 8-18. [DOI:10.1002/biof.67]

19. Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, et al. Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nat Commun. 2019; 10(1): 1146. [DOI:10.1038/s41467-019-08480-y]

20. Qi C, Lei L, Hu J, Wang G, Liu J, Ou S. Thrombospondin-1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma. Oncol Lett. 2021; 21(1): 22. [DOI:10.3892/ol.2020.12283]

21. Lu T, Li C, Xiang C, Gong Y, Peng W, Hou F, et al. Over-expression of NFYB affects stromal cells reprogramming and predicts worse survival in gastric cancer patients. Aging (Albany NY). 2022; 14(19): 7851-67. [DOI:10.18632/aging.204294]

22. Yu Z, Ouyang L. OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer. Discover Oncology. 2023; 14(1): 159. [DOI:10.1007/s12672-023-00778-0]

23. Chen W, Zou A, Zhang H, Fu X, Yao F, Yang A. Odd-skipped related transcription factor 1 (OSR1) suppresses tongue squamous cell carcinoma migration and invasion through inhibiting NF-κB pathway. Eur J Pharmacol. 2018; 839: 33-9. [DOI:10.1016/j.ejphar.2018.09.020]

24. Zhang Y, Yuan Y, Liang P, Guo X, Ying Y, Shu X-S, et al. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma. Oncotarget. 2017; 8(18): 30008-18. [DOI:10.18632/oncotarget.15611]

25. Wang Y, Lei L, Xu F, Xu H-T. Reduced expression of odd-skipped related transcription factor 1 promotes proliferation and invasion of breast cancer cells and indicates poor patient prognosis. Oncol Lett. 2020; 20(3): 2946-54. [DOI:10.3892/ol.2020.11820]

26. Chen, WL, Wang, CC, Lin, YJ. Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. 2015; 13: 389. [DOI:10.1186/s12967-015-0758-8]

27. Lin W, Wu S, Chen X, Ye Y, Weng Y, Pan Y, Chen Z, Chen L, Qiu X and Qiu S. Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups. Front. Oncol. 2020; 10: 796. [DOI:10.3389/fonc.2020.00796]

28. L. Oliver, C. Olivier, F. B. Marhuenda, M. Campone, F. M. Vallette, Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy, Current Molecular Pharmacology; Volume 2, Issue 3, Year 2009; 263-284. [DOI:10.2174/1874467210902030263]

29. Pouyan, A., Ghorbanlo, M., Eslami, M. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.2025; 24: 25. [DOI:10.1186/s12943-025-02267-0]

30. Ding Y, et al. CRISPR-based functional genomics identifies OSR1 in PI3K/AKT pathway regulation. Cell Rep. 2024; 42(2): 112154.

31. Uzzaman A, Zhang X, Qiao Z, Zhan H, Sohail A, Wahid A, et al. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer. Biochimie. 2020; 177: 132-41. [DOI:10.1016/j.biochi.2020.08.013]

32. Li Y, Qin J, Chen G, Liu J, Lin Y, Wang Y, et al. Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer. Int J Clin Oncol. 2024; 29(4): 427-41. [DOI:10.1007/s10147-024-02472-9]

33. Tang Y-F, Wang Y-Z, Wen G-B, Jiang J-J. Prognostic model of kidney renal clear cell carcinoma using aging-related long noncoding RNA signatures identifies THBS1-IT1 as a potential prognostic biomarker for multiple cancers. Aging (Albany NY). 2023; 15(17): 8630-49. [DOI:10.18632/aging.204949]

34. Kaur S, Bronson SM, Pal-Nath D, Miller TW, Soto-Pantoja DR, Roberts DD. Functions of Thrombospondin-1 in the Tumor Microenvironment. International Journal of Molecular Sciences. 2021; 22(9): 4570. [DOI:10.3390/ijms22094570]

35. Whitehead CA, Morokoff AP, Kaye AH, Drummond KJ, Mantamadiotis T, Stylli SS. Invadopodia associated thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells. Exp Cell Res. 2023; 431(1): 113743. [DOI:10.1016/j.yexcr.2023.113743]

36. Guo, W-F., Lin, R-X., Huang, J., Zhou, Z., Yang, J., Guo, G-Z. and Wang, S-Q. Identification of Differentially Expressed Genes Contributing to Radioresistance in Lung Cancer Cells using Microarray Analysis. Radiat. Res. 2005; 164(1): 27-35. [DOI:10.1667/RR3401]

37. Michna, A., Schötz, U., Selmansberger, M. et al. Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks. 2016; 11: 94 [DOI:10.1186/s13014-016-0672-0]

38. Jun Guo, Anahita Fathi Kazerooni, Hamed Akbari, Erik Toorens, Chiharu Sako, elizabeth mamourian, constantinos koumenis, stephen bagley, zev a binder, robert lustig, donald o'rourke, tapan ganguly, spyridon bakas, maclean nasrallah, christos davatzikos, nimg-37. joint learning of imaging and genomic data reveals distinct glioblastoma subtypes, Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii171. [DOI:10.1093/neuonc/noac209.655]

39. Mohammad Fayyad Zaman, Marc Daou, Lynette M Phillips, Sanjay Singh, Lihong Long, Joy Gumin, Daniel Ledbetter, Frederick F Lang, tmic-46. transcriptional heterogeneity and mechanistic pathways of recurrent glioblastoma: insights from a pre-clinical recurrent tumor model, Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024. [DOI:10.1093/neuonc/noae165.1224]

40. Liu P, Xing N, Xiahou Z, Yan J, Lin Z, Zhang J. Unraveling the intricacies of glioblastoma progression and recurrence: insights into the role of NFYB and oxidative phosphorylation at the single-cell level. Front Immunol. 2024; 15: 1368685. [DOI:10.3389/fimmu.2024.1368685]

41. Choi J, Kim G, Cho SB, Im H-J. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme. J Nanobiotechnology. 2020; 18(1): 122. [DOI:10.1186/s12951-020-00684-5]

42. Khabibov M, Garifullin A, Boumber Y, Khaddour K, Fernandez M, Khamitov F, et al. Signaling pathways and therapeutic approaches in glioblastoma multiforme. Int J Oncol. 2022; 60(6): 69. [DOI:10.3892/ijo.2022.5359]

43. Ou A, Yung WA, Majd N. Molecular mechanisms of treatment resistance in glioblastoma. Int J Mol Sci. 2021; 22(1): 351. [DOI:10.3390/ijms22010351]

44. Stanzani E, Martínez-Soler F, Mateos T. Martín, Vidal N, Villanueva A, Pujana M. Angel, Serra-Musach J., de la Iglesia N., Giménez-Bonafé P., Tortosa A. Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program. Oncotarget. 2017; 8: 73640-73653. [DOI:10.18632/oncotarget.18363]

45. Georg Emons; Melanie Spitzner; Sebastian Reineke; Janneke Möller; Noam Auslander; Frank Kramer, et al. Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling. Mol Cancer Res 2017; 15(11): 1481-1490. [DOI:10.1158/1541-7786.MCR-17-0205]

46. Masoumeh Eliyasi Dashtaki, Elham Karimi, Sorayya Ghasemi. Genetic Variants Impacting Angiogenesis Signaling Pathways in Glioblastoma Multiforme: A Systematic Review of Mutations and Polymorphisms. Current Molecular Medicine, 2024; 11: 1346-1357. [DOI:10.2174/1566524023666230725115812]

47. Yin, J, Ding, F, Cheng, Z. METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling. 2023; 14: 417(2023). [DOI:10.1038/s41419-023-05933-7]

48. Xue, C., Chu, Q., Shi, Q. et al. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.2025; 10: 106. [DOI:10.1038/s41392-025-02142-w]

49. Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. N Am J Med Sci. 2018; 10(9): 671-7.

50. Moffitt JR, Lundberg E, Heyn H. The emerging landscape of spatial profiling technologies. Nat Rev Genet. 2022; 23(12): 741-59. [DOI:10.1038/s41576-022-00515-3]

51. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2018; 173(1): 20-51. [DOI:10.1016/j.cell.2018.03.006]

52. Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, et al. Peripherally driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021; 9(11): e003609. [DOI:10.1136/jitc-2021-003609]

53. Derynck R, Turley SJ, Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021; 18(1): 9-34. [DOI:10.1038/s41571-020-0403-1]

54. Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018; 18(5): 309-24. [DOI:10.1038/nri.2017.142]

55. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019; 178(4): 835-49.e21. [DOI:10.1016/j.cell.2019.06.024]